Our Products
Loans
Cards
Insurance
Investment
Stock Market
Electronics Mall
CIBIL Score
Knowledge Centre
Academy 
Calculators
Our Services
My Account
Do not call
En
Nifty500 Momentum 50
Nifty500 Momentum 50 Performance
Day's Range
Low
₹53,458.95
High
₹54,017.45
52 Week Range
Low
₹45,696.80
High
₹55,427.85
| Previous Close | ₹53,835.75 |
|---|---|
| Day's Range | ₹53,458.95 - ₹54,017.45 |
| Open | ₹53,965.90 |
| 52 Week Range | ₹45,696.80 - ₹55,427.85 |
| Volume | 47,21,11,147 |
Nifty500 Momentum 50 Companies
| Company Name | LTP (₹) | Change (₹) | Sector |
|---|---|---|---|
| ABB India Ltd. | 6861.00 |  -76.00 (-1.10%) |
Capital Goods |
| CG Power and Industrial Solutions Ltd. | 959.40 | -17.10 (-1.75%) |
Capital Goods |
| Bharat Heavy Electricals Ltd. | 401.95 | -12.00 (-2.90%) |
Capital Goods |
| Steel Authority Of India Ltd. | 168.12 | -0.15 (-0.09%) |
Iron & Steel |
| Finolex Cables Ltd. | 1129.80 | -14.70 (-1.28%) |
Electricals |
| HFCL Ltd. | 204.59 | -7.50 (-3.54%) |
Telecom |
| Thermax Ltd. | 4917.00 | -203.50 (-3.97%) |
Capital Goods |
| Torrent Pharmaceuticals Ltd. | 4661.40 |  20.60 (0.44%) |
Healthcare |
| Hindalco Industries Ltd. | 949.20 | 9.50 (1.01%) |
Non - Ferrous Metals |
| The Federal Bank Ltd. | 331.00 | -0.40 (-0.12%) |
Bank |
| Index Name | Market Value | 52W High | 52W Low |
|---|---|---|---|
| Nifty 50 | 24175.7 | 26373.20 | 22182.55 |
| Nifty IT | 26965.05 | 40301.40 | 25699.10 |
| Nifty Next 50 | 72418.55 | 73141.05 | 59896.10 |
| NIFTY50 USD Index | 8780.15 | 10443.40 | 8132.40 |
| Nifty Bank | 58031.65 | 61764.85 | 49954.85 |
| NIFTY Midcap 100 | 62307.9 | 62909.55 | 52032.85 |
| Nifty 500 | 23264.8 | 24144.20 | 20385.65 |
| Nifty Midcap 50 | 17806.0 | 17859.10 | 14804.55 |
| Nifty 100 | 25230.2 | 26975.15 | 22720.45 |
| Nifty FMCG | 50084.7 | 58485.05 | 45334.15 |
Latest News
Glenmark Pharmaceuticals informs about media release
Glenmark Pharmaceuticals has informed that, Glenmark Specialty S.A, a wholly owned subsidiary of the company (Glenmark) announced the advancement of its multi-country Phase 3 clinical trial for Trastuzumab rezetecan (SHR-A1811), a HER2-targeted antibody drug conjugate (ADC), for patients with platinum-resistant ovarian cancer (PROC). India will serve as the first country in Glenmark’s licensed markets to initiate patient enrollment for the Phase 3 clinical trial, following the approval of Drugs Controller General of India (DCGI). Glenmark also plans to enroll patients in Australia and South Korea, subject to regulatory approvals. The company has attached media release.
The above information is a part of company’s filings submitted to BSE.
CG Power and Industrial Solutions informs about newspaper advertisements
Pursuant to Regulation 30, Regulation 44 and Regulation 47 of the SEBI Listing Regulations and in compliance with Section 108 of the Companies Act, 2013 read with Rule 20 of the Companies (Management and Administration) Rules, 2014, CG Power and Industrial Solutions has informed that it enclosed copies of Newspaper Advertisements published in Business Standards and Loksatta newspapers, informing about the Notice of 89th Annual General Meeting of the Company scheduled to be held on Friday, 24th July, 2026 at 03:00 pm.
The above information is a part of company’s filings submitted to BSE.
Bharat Heavy Electricals informs about outcome of board meeting
Karur Vysya Bank informs about reliving of senior management personnel
Hindustan Copper informs about change in directorate
No Records Found
Sign in to Unlock Offers!
We don't SPAM
Frequently Asked Questions
The previous close of NFT500MOM50 index is ₹53701.85 as of 2026-07-02.
The total volume of NFT500MOM50 index is 472111147.00 as of 2026-07-02.
The percentage change in value of NFT500MOM50 index is -0.25% as of 2026-07-02.
The absolute increase in NFT500MOM50 index value since the previous trading day is ₹-133.9 as of 2026-07-02.
A stock reaching its 52-week high indicates it has attained its highest price point in the past year. This milestone may signal strong performance and positive investor sentiment. Please note that investments are subject to market risks.
Disclaimer
All content and research information displayed on the Site, are obtained from our partner Accord Fintech Private Limited. an authorized data feed vendor of BSE/NSE/MCX/NCDEX exchange. The data is provided on ‘As-Is’ basis and is not a live data feed but a feed with 15 minutes delay or more. Bajaj Markets does not warrant accuracy, completeness, timely availability of the information and data available on the Site. Past performance, when presented, is purely for reference purposes and is not a guarantee of similar future results.
The Services offered on the Site does not constitute investment advice in any manner whatsoever. You shall be solely responsible for any investment decisions made by placing reliance on the information provided on the Site.
Bajaj Markets partners with financial services entities for sourcing leads for services such as DEMAT accounts etc. In case you wish to avail the services, you shall be redirected to partners platform and shall be bound by the terms and conditions, privacy policy governing the said platform.
